PTEN Expression, Not Mutation Status in TSC1, TSC2 , or mTOR , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial - Voss, Martin H.; Chen, David; Reising, Albert; Marker, Mahtab; Shi, Jiayuan; Xu, Jianning; Ostrovnaya, Irina; Seshan, Venkatraman E.; Redzematovic, Almedina; Chen, Ying-Bei; Patel, Parul; Han, Xia; et al. (Clinical cancer research, 2019)
Keywords: Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor; Carcinoma, Renal Cell - diagnosis; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - mortality; Everolimus - administration & dosage; Everolimus - adverse effects; Everolimus - therapeutic use; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Kidney Neoplasms - diagnosis; Kidney Neoplasms - drug therapy; Kidney Neoplasms - genetics; Kidney Neoplasms - mortality; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; PTEN Phosphohydrolase - genetics; PTEN Phosphohydrolase - metabolism; Retreatment; TOR Serine-Threonine Kinases - genetics; Treatment Outcome; Tuberous Sclerosis Complex 1 Protein - genetics; Tuberous Sclerosis Complex 2 Protein - genetics